Cover Image
市場調查報告書

肝性腦病變:開發中產品分析

Hepatic Encephalopathy - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213083
出版日期 內容資訊 英文 64 Pages
訂單完成後即時交付
價格
Back to Top
肝性腦病變:開發中產品分析 Hepatic Encephalopathy - Pipeline Review, H2 2016
出版日期: 2016年07月13日 內容資訊: 英文 64 Pages
簡介

所謂肝性腦病變是指肝臟無法消除血液中有害物質,造成腦功能隨之惡化的疾病。主要的症狀為喪失方向感、嗜睡、意識障礙、睡眠模式的變化、語言障礙、興奮、(在某些情況下)中風等。主要的易罹病素質包含腸胃出血和蛋白質攝取量的增加、高氮血症的腎功能不全、(伴隨氮攝取量增加)便秘、醫藥品(特別是鎮靜劑、利尿劑)、低氧症等。

本報告提供全球各國治療肝性腦病變所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查,並將結果概述為以下內容。

目錄

簡介

  • 分析範圍

肝性腦病變概要

治療藥的開發

  • 肝性腦病變開發中產品:概要
  • 肝性腦病變開發中產品:比較分析

各企業開發中的肝性腦病變治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

肝性腦病變治療藥:開發中的產品一覽(各企業)

肝性腦病變治療藥的開發企業

  • Alfa Wassermann S.p.A
  • Cosmo Pharmaceuticals S.p.A
  • Horizon Pharma Plc
  • KannaLife Sciences, Inc.
  • Ocera Therapeutics, Inc.
  • Rebiotix Inc.
  • Spherium Biomed S.L.
  • Umecrine Cognition AB

肝性腦病變:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

肝性腦病變治療藥:開發暫停的產品

肝性腦病變相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8227IDB

Summary

Global Markets Direct's, 'Hepatic Encephalopathy - Pipeline Review, H2 2016', provides an overview of the Hepatic Encephalopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hepatic Encephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatic Encephalopathy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hepatic Encephalopathy
  • The report reviews pipeline therapeutics for Hepatic Encephalopathy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hepatic Encephalopathy therapeutics and enlists all their major and minor projects
  • The report assesses Hepatic Encephalopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hepatic Encephalopathy

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hepatic Encephalopathy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hepatic Encephalopathy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hepatic Encephalopathy Overview
  • Therapeutics Development
    • Pipeline Products for Hepatic Encephalopathy - Overview
  • Hepatic Encephalopathy - Therapeutics under Development by Companies
  • Hepatic Encephalopathy - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Hepatic Encephalopathy - Products under Development by Companies
  • Hepatic Encephalopathy - Companies Involved in Therapeutics Development
    • Alfa Wassermann S.p.A
    • Cosmo Pharmaceuticals S.p.A
    • Horizon Pharma Plc
    • KannaLife Sciences, Inc.
    • Ocera Therapeutics, Inc.
    • Rebiotix Inc.
    • Spherium Biomed S.L.
    • Umecrine Cognition AB
  • Hepatic Encephalopathy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • glycerol phenylbutyrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GR-3027 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KLS-13019 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ornithine phenylacetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RBX-2477 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rifamycin CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rifaximin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • THDP-17 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hepatic Encephalopathy - Dormant Projects
  • Hepatic Encephalopathy - Product Development Milestones
    • Featured News & Press Releases
      • Apr 15, 2016: Ocera Therapeutics Announces Presentation of Two Preclinical Studies Further Supporting Its Ammonia Scavenger OCR-002 at The International Liver Congress 2016 of the European Association for the Study of the Liver (EASL)
      • Apr 11, 2016: Ocera Therapeutics Announces Publication of Promising Preclinical Data in Support of Its Ammonia Scavenger OCR-002 in the Journal of Hepatology
      • Jan 08, 2016: Ocera Announces Complete Plasma Data From Pilot Phase 1 Study for Orally-Available OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy
      • Dec 09, 2015: Umecrine Cognition Announces Grant Of a US Patent Protecting Its Lead Candidate Drug GR3027
      • Nov 16, 2015: Ocera Announces Positive Phase 1 Results for Oral OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy
      • Sep 16, 2015: Ocera Initiates Phase 1 Clinical Trial of Oral Drug Candidate OCR-002 for Prevention of Hepatic Encephalopathy
      • Aug 19, 2015: Umecrine Cognition announces the publication of preclinical results of the candidate drug GR3027 aimed for the treatment of hepatic encephalopathy
      • Aug 11, 2015: Kannalife Sciences Discusses Orphan Drug Opportunity for KLS-13019
      • Apr 20, 2015: Lupin Launches Zaxine in Canada
      • Apr 01, 2015: Ocera Completes Interim Analysis of OCR-002 in Phase 2b STOP-HE Study for the Treatment of Acute Hepatic Encephalopathy
      • Sep 18, 2014: Salix Secures Additional Intellectual Property Relating to Rifaximin
      • Sep 12, 2014: Lupin and Salix Announce Exclusive Distribution Agreement for Zaxine in Canada
      • Feb 25, 2014: Hyperion Therapeutics Announces the Publication of Phase 2 Results of Glycerol Phenylbutyrate for the Treatment of Hepatic Encephalopathy in Hepatology
      • Feb 14, 2014: Luxembourg National Health Fund Approves Reimbursement Of Xifaxan 550
      • Feb 04, 2014: Salix Pharmaceuticals Announces Issuance Of U. S. Patent For Rifaximin
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hepatic Encephalopathy, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Hepatic Encephalopathy - Pipeline by Alfa Wassermann S.p.A, H2 2016
  • Hepatic Encephalopathy - Pipeline by Cosmo Pharmaceuticals S.p.A, H2 2016
  • Hepatic Encephalopathy - Pipeline by Horizon Pharma Plc, H2 2016
  • Hepatic Encephalopathy - Pipeline by KannaLife Sciences, Inc., H2 2016
  • Hepatic Encephalopathy - Pipeline by Ocera Therapeutics, Inc., H2 2016
  • Hepatic Encephalopathy - Pipeline by Rebiotix Inc., H2 2016
  • Hepatic Encephalopathy - Pipeline by Spherium Biomed S.L., H2 2016
  • Hepatic Encephalopathy - Pipeline by Umecrine Cognition AB, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Hepatic Encephalopathy - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Hepatic Encephalopathy, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top